| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/16/2001 | EP1123115A1 Treatment of trauma (ie graft rejection) with liposomes containing dna encoding for ctla4ig or for anti cd40l |
| 08/16/2001 | EP1123113A1 Ribozymes used as prodrugs |
| 08/16/2001 | EP1123111A1 Modulation of gene expression by combination therapy |
| 08/16/2001 | EP1123097A1 Pharmaceutical composition containing decursin |
| 08/16/2001 | EP1123091A1 Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use |
| 08/16/2001 | EP1123090A1 Method and composition for modulating amyloidosis |
| 08/16/2001 | EP1123088A1 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor |
| 08/16/2001 | EP1123082A1 Preparations for topical application of substances having antiandrogenic effect |
| 08/16/2001 | EP1123072A1 Anti-inflammatory and antimicrobial uses for bioactive glass compositions |
| 08/16/2001 | EP1035851B1 Endothelin receptor antagonists for combating hyperlipidaemia |
| 08/16/2001 | EP0939635B1 Improved intraocular irrigating solution containing a polyamine antagonist |
| 08/16/2001 | EP0771189B1 Inhalation composition |
| 08/16/2001 | DE10004858A1 Verwendung von Proteinkinase-Inhibitor-alpha The use of protein kinase inhibitor alpha- |
| 08/16/2001 | DE10004651A1 Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen Combination of antihypertensive agents with agents that are able to reduce homocysteine levels |
| 08/16/2001 | CA2800450A1 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/16/2001 | CA2736615A1 Method for classifying and treating physiologic brain imbalances using quantitative eeg |
| 08/16/2001 | CA2714081A1 Methods and compositions for treating conditions of the eye |
| 08/16/2001 | CA2400699A1 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 08/16/2001 | CA2400472A1 Il-17 like molecules and uses thereof |
| 08/16/2001 | CA2400299A1 Dna encoding human vanilloid receptor vr3 |
| 08/16/2001 | CA2400187A1 Protein c derivatives |
| 08/16/2001 | CA2399945A1 Larynx carcinoma-associated protein larcap-1 |
| 08/16/2001 | CA2399944A1 Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases |
| 08/16/2001 | CA2399873A1 Drug metabolizing enzymes |
| 08/16/2001 | CA2399821A1 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof |
| 08/16/2001 | CA2399791A1 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| 08/16/2001 | CA2399623A1 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 08/16/2001 | CA2399593A1 Antibodies to ccr5 |
| 08/16/2001 | CA2399463A1 Combination drug |
| 08/16/2001 | CA2399436A1 Method of treating or inhibiting cellular injury or cell death |
| 08/16/2001 | CA2399421A1 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
| 08/16/2001 | CA2399402A1 Use of cyp1b1 inhibitors for treating cancer |
| 08/16/2001 | CA2399387A1 Heterologous polypeptide of the tnf family |
| 08/16/2001 | CA2399148A1 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/16/2001 | CA2398840A1 Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| 08/16/2001 | CA2398775A1 Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization |
| 08/16/2001 | CA2398567A1 Methods for enhancing the bioavailability of a drug |
| 08/16/2001 | CA2398282A1 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 08/16/2001 | CA2398184A1 Method and compositions for treating an inflammatory disease |
| 08/16/2001 | CA2398158A1 Ophthalmic use of alpha adrenergic blocking agents |
| 08/15/2001 | CN1308677A Human tumour-derived polyptde hormone phosphatonin |
| 08/15/2001 | CN1308544A Treatment for diabetes |
| 08/15/2001 | CN1308538A Treatment of hyperproliferative disorders |
| 08/15/2001 | CN1308533A Agent with an antidepressive effect |
| 08/15/2001 | CN1308530A Use of tricyclic antidepressants for local analgesia |
| 08/15/2001 | CN1308525A Transdermal plaster containing at least one active ingredient which infuences blood serum lipid levels |
| 08/15/2001 | CN1307901A Treating synergist composite and its usage |
| 08/15/2001 | CN1069545C Antiseptic and antivirotic medicinal composition and preparation process thereof |
| 08/15/2001 | CA2337381A1 Compositions and methods for treating osteoporosis |
| 08/14/2001 | US6274719 Polynucleotides and polypeptides of the glycopeptidase family; human streptococci microbe diseases targets for development of antibiotics; otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, endocarditis |
| 08/14/2001 | US6274629 Use for 1,3-propanediol derivatives |
| 08/14/2001 | US6274611 Methods and compositions for inhibition of viral replication |
| 08/14/2001 | US6274605 Administering an insulin sensitivity enhancer with an angiotensin converting enzyme inhibitor to reduce side effects to a diabetic patient |
| 08/14/2001 | US6274604 Alteration of circadian rhythmicity with a tachykinin antagonist |
| 08/14/2001 | US6274603 Administering probucol or an analog to treat alzheimer's disease |
| 08/14/2001 | US6274602 Administering compostitions such as 3,3-dimethyl-1-((2s)-2-(5-(3-pyridyl) pentanoyl)-1-pyrrolidine)-1, 2-pentanedione to treat alopecia or promoting hair growth in animals |
| 08/14/2001 | US6274592 Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid |
| 08/14/2001 | US6274582 Reduction of visceral fat |
| 08/14/2001 | US6274581 Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| 08/14/2001 | US6274576 Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
| 08/14/2001 | US6274574 Use of mesophase-stabilized compositions for delivery of cholesterol-reducing sterols and stanols in food products |
| 08/14/2001 | US6274566 Methods for treating mammals with modified alginates and pectins |
| 08/14/2001 | US6274563 Administering as antidiabetic agent |
| 08/14/2001 | US6274561 Synergistic mixture of silamine and adriamycin; side effect reduction |
| 08/14/2001 | US6274552 Targeting tissue with tumor necrosis factor mixed or bound to colloidal metal; anticarcinogenic agents, autoimmune diseases |
| 08/14/2001 | US6274336 Producing three-dimensional structure of active site using computer program, displaying and superimposing three-dimensional representation of test compound onto active site, preparing test compound, and testing in biological assay |
| 08/14/2001 | US6274173 Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| 08/14/2001 | US6274170 Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same |
| 08/14/2001 | US6274161 Compositions containing creatine in suspension |
| 08/14/2001 | US6274142 Neutralizing coagulant activity of tissue factor by administering antibody which binds to tissue factor protein and neutralizes |
| 08/14/2001 | US6273908 Stents |
| 08/14/2001 | CA2206824C Inhibitors of rotamase enzyme activity |
| 08/10/2001 | CA2331876A1 Water-soluble ligand-binding proteins and analogs of ligand-gated channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 08/09/2001 | WO2001057267A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | WO2001057265A1 Methods and materials relating to metallocarboxypeptidase-like polypeptides and polynucleotides |
| 08/09/2001 | WO2001057261A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | WO2001057242A2 Methods of protein destabilization and uses thereof |
| 08/09/2001 | WO2001057240A2 Interaction of nmda receptor with protein tyrosine phosphatase |
| 08/09/2001 | WO2001057210A2 Use of dendroaspin as a vehicle for non-dendroaspin domains |
| 08/09/2001 | WO2001057194A2 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 08/09/2001 | WO2001057193A2 Protein c derivatives |
| 08/09/2001 | WO2001057085A2 G-protein coupled receptors |
| 08/09/2001 | WO2001057078A1 Process for producing dialytic amyloid fiber polymerization nuclei, method of screening remedies for dialytic amyloidosis and remedies for dialytic amyloidosis |
| 08/09/2001 | WO2001057069A2 Targeting peptides |
| 08/09/2001 | WO2001057060A1 Bcl-2-like polynucleotides, polypeptides, and antibodies |
| 08/09/2001 | WO2001057059A1 Antisense modulation of survivin expression |
| 08/09/2001 | WO2001057036A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
| 08/09/2001 | WO2001057025A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 08/09/2001 | WO2001057022A2 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001056959A1 A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome |
| 08/09/2001 | WO2001056609A1 Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments |
| 08/09/2001 | WO2001056607A1 Integrin expression inhibitors |
| 08/09/2001 | WO2001056590A2 Utilization of protein kinase inhibitor alpha |
| 08/09/2001 | WO2001056579A1 Methods for treating alzheimer's disease |
| 08/09/2001 | WO2001056573A1 Use of cox-2 inhibitors as gastroprokinetics |
| 08/09/2001 | WO2001056571A1 Treating allergic and inflammatory conditions |
| 08/09/2001 | WO2001056563A1 Adamantyl derivatives as anti-cancer agents |
| 08/09/2001 | WO2001056555A2 Use of cox-2 inhibitors for the treatment of constipation |
| 08/09/2001 | WO2001056554A2 Use of retinoid-type compounds as antibacterial agents |
| 08/09/2001 | WO2001056553A2 Pharmaceutically active aromatic guanylhydrazones |